How Radiation Therapy Affects the Immune System

Radiation therapy reshapes the immune system in two opposing directions at once. A beam aimed at a tumor can release hidden tumor proteins that teach immune cells to recognize and attack cancer, while simultaneously killing the very lymphocytes needed to carry out that attack. Which effect dominates depends on factors like the radiation dose, the size of the treatment field, the type of particle used, and the patient’s own immune health. Understanding this push-and-pull is central to modern oncology, especially as doctors increasingly pair radiation with immunotherapy drugs.

How Radiation Triggers an Immune Alarm

When radiation damages a cancer cell badly enough, the cell does not simply die quietly. It undergoes a form of death called immunogenic cell death, during which it releases a set of internal distress signals. These signals include damage-associated molecular patterns and immunostimulatory cytokines that draw the attention of nearby immune cells, particularly dendritic cells, which are the sentinels responsible for alerting the rest of the immune system. The dying cancer cell essentially becomes a beacon, broadcasting both “something is wrong here” and fragments of its own proteins that dendritic cells can collect and present to T cells.¹

A crucial piece of this alarm system involves DNA fragments that spill into a cell’s interior fluid after radiation shatters chromosomes. A sensor called cGAS detects this misplaced DNA and activates a downstream partner called STING, which triggers the production of type I interferons. These interferons are powerful immune-activating molecules that help dendritic cells mature and cross-prime killer T cells against tumor proteins.² Experiments with dendritic cells lacking cGAS showed they could not prime T cells against irradiated tumor cells at all, but adding interferon-beta back into the mix restored the response, confirming how essential this pathway is.³

Making Tumor Cells More Visible to Immune Attack

Beyond triggering an alarm, radiation forces cancer cells to display more of their internal contents on their outer surface. Every cell carries surface molecules called MHC class I that act like display windows, presenting small protein fragments to passing T cells. Many tumors survive partly by reducing these display molecules, making themselves nearly invisible. Radiation reverses that trick. After irradiation, MHC class I expression increases in a dose-dependent manner and stays elevated for days. The increase comes from multiple sources: existing proteins are broken down faster, new proteins are made in greater quantities, and entirely new proteins appear that the cell did not produce before radiation.⁴

The scale of this effect can be dramatic. In one study using a mouse colorectal cancer model, MHC class I molecule levels roughly doubled to tripled within 48 to 72 hours after radiation.⁵ Irradiated cells also release interferon-beta, which can boost MHC class I expression even on neighboring unirradiated cancer cells. Blocking interferon-beta with a neutralizing antibody reduced this secondary effect, showing that the signal spreads through secreted molecules rather than requiring direct radiation damage.⁶ The practical consequence is that radiation turns a tumor into something the immune system can see and respond to, functioning as a kind of in situ vaccine.

The Abscopal Effect

One of the most tantalizing immune phenomena linked to radiation is the abscopal effect, where treating a tumor in one part of the body causes untreated tumors elsewhere to shrink. The mechanism follows logically from everything above: radiation at the primary site releases tumor antigens and activates dendritic cells, which prime T cells that then circulate through the bloodstream and find tumor deposits in distant locations.⁷

Historically, the abscopal effect was extremely rare with radiation alone. The immune-suppressive environment inside most tumors was enough to blunt whatever systemic response radiation generated. That changed with the arrival of immune checkpoint inhibitors, drugs that release the brakes on T cells. When immunotherapy keeps T cells active and radiation provides them with fresh tumor targets, the combination can amplify a systemic response. Clinical reports of abscopal responses have increased since the two modalities started being combined.⁸ Still, the abscopal effect remains unpredictable, and researchers are working to understand why some patients experience it and most do not.

How Radiation Suppresses the Immune System

For all its immune-activating potential, radiation is also a potent immune suppressor. Lymphocytes are among the most radiation-sensitive cells in the body, and even modest doses can kill them in large numbers. A condition called radiation-induced lymphopenia, a measurable drop in circulating lymphocyte counts, is common during standard treatment courses and has been linked to worse survival outcomes.⁹ The risk increases when the radiation field is large, because more blood and lymphoid tissue passes through the treatment zone. Incidental radiation to the spleen is one contributor: in a retrospective study, each additional gray of mean splenic dose was associated with about a one percent drop in the lowest lymphocyte count during treatment.¹⁰

Radiation also recruits immunosuppressive cells to the tumor. Myeloid-derived suppressor cells move into the area through a chemokine-driven mechanism linked, ironically, to the same cGAS-STING pathway that triggers immune activation. Once present, these cells suppress T-cell activity by producing reactive oxygen species, nitric oxide, and enzymes that degrade amino acids T cells need to function.¹¹ Additionally, radiation triggers the release of TGF-beta, a powerful immunosuppressive molecule. TGF-beta promotes the development of regulatory T cells that actively shut down anti-tumor responses, pushes macrophages toward a tumor-supporting state, and suppresses killer T cells and natural killer cells.¹² In normal tissue, radiation-induced TGF-beta also drives fibrosis, the long-term scarring that is one of radiation’s well-known side effects.¹³

So the same treatment simultaneously activates immune cells, kills immune cells, and recruits immune-suppressive cells. The net result depends heavily on how the radiation is delivered.

Macrophage Reprogramming Inside the Tumor

Tumors are often infiltrated by macrophages, immune cells that can either fight cancer or help it grow depending on their programming. Tumor-associated macrophages frequently adopt an “M2” state that suppresses immune activity, promotes blood vessel growth for the tumor, and helps it evade destruction. Radiation at moderate doses, roughly 5 to 10 gray, can reprogram these macrophages from the tumor-supporting M2 state toward an M1 state that produces inflammatory signals and recruits T cells.¹⁴

Low-dose radiation has shown a particularly interesting version of this effect. In a mouse model, a single 2-gray dose induced macrophages to switch on iNOS, an enzyme that produces nitric oxide, while simultaneously reducing markers of the M2 state. The switch was accompanied by improved blood vessel function within the tumor and increased T-cell infiltration, suggesting that low-dose radiation can remodel the tumor’s internal environment to make it more hospitable for immune attack.¹⁵ This is part of why some researchers now think of radiation less as a blunt killing tool and more as a way to reshape the tumor microenvironment.

Why Dose and Fractionation Matter So Much

The immune consequences of radiation shift dramatically depending on the dose per fraction and the number of fractions delivered. Conventional fractionation, where patients receive small daily doses of one to three gray over several weeks, tends to increase local cytokine production and upregulate stress markers on tumor cells, but it can also kill infiltrating T cells that are trying to do their job inside the tumor. Moderate hypofractionation, such as three sessions of eight gray each, appears to strike a better balance by generating a stronger interferon response while still allowing immune cells time between treatments to regroup. Ablative single doses of 20 gray or more cause massive cell death and can wipe out immune-suppressive cells in the tumor, but they also increase fibrosis and may trigger chronic inflammatory pathways that ultimately suppress immunity.¹⁶

This is why the field has not settled on a single “immunogenic dose.” When radiation is combined with checkpoint inhibitors in patients with metastatic disease, hypofractionated regimens of one to five fractions are commonly used, sometimes at intentionally sub-ablative doses designed more for immune modulation than outright tumor killing. The right dose depends on the goal: priming an immune response looks different from sterilizing a tumor, and the two objectives do not always align.

Particle Type Changes the Immune Picture

Most radiation therapy uses photons (X-rays), but proton therapy and carbon-ion therapy are increasingly available. These particle types do not just differ in how they deposit energy in tissue; they also differ in how they affect the immune system. Comparisons of photon and carbon-ion radiation in tumor models have found that photon radiation reduced both CD4+ and CD8+ T-cell populations within tumors at every dose tested, while carbon-ion radiation preserved CD8+ T-cell infiltration. High-dose carbon-ion treatment increased the secretion of several pro-inflammatory cytokines by those infiltrating T cells, including granzyme B, a molecule directly involved in killing cancer cells. Photon radiation, by contrast, mainly boosted just one cytokine, interferon-gamma. Carbon-ion radiation also triggered less expansion of immunosuppressive regulatory T cells at most dose levels.¹⁷

Another difference involves calreticulin, a protein that moves to the surface of dying cells and signals immune cells to eat them. At lower doses of two to four gray, carbon-ion radiation was significantly more effective than either photon or proton radiation at pushing calreticulin to the cell surface. At higher doses, the advantage reversed.¹⁸ These findings suggest that different particles may be better matched to different immunotherapy strategies, though clinical trials are still needed to confirm whether the immune differences seen in lab models translate into better outcomes for patients.

FLASH Radiotherapy and Immune Sparing

An emerging technique called FLASH radiotherapy delivers the entire radiation dose in an ultra-short burst, typically less than a second, at dose rates hundreds of times higher than conventional treatment. Preclinical evidence suggests that FLASH radiation produces a notably different immune profile compared to standard delivery. It appears to reduce lymphocyte depletion, enhance CD8+ T-cell infiltration into tumors, and lower levels of immunosuppressive factors like TGF-beta and PD-L1.¹⁹ If these findings hold up in human trials, FLASH could address one of radiation’s central paradoxes by preserving the immune cells that conventional delivery destroys while still killing the tumor. The technology is still early in clinical testing, but the immune-sparing angle is one of the main reasons it has generated so much excitement.

Combining Radiation With Immunotherapy

The rationale for pairing radiation with immune checkpoint inhibitors pulls together many of the threads above. Radiation releases tumor antigens, increases MHC display, and activates the cGAS-STING pathway, essentially priming an immune response. Checkpoint inhibitors then remove the molecular brakes that tumors use to shut that response down. The combination can increase T-cell infiltration into the tumor and expand populations of cancer-specific killer T cells, creating conditions for both local and distant tumor control.^{20 21}

A practical concern with this combination is whether it creates additive toxicity. A pooled analysis of trials in the FDA database found that patients receiving radiation alongside immunotherapy had generally similar rates of adverse events to those receiving immunotherapy alone, with an average absolute difference of just over one percent across event types and no meaningful difference in severe side effects.²² That said, specific overlapping toxicities do exist. In lung cancer, both thoracic radiation and checkpoint inhibitors can cause pneumonitis, and the overlap demands careful monitoring when the two are used concurrently.²³ A systematic review of stereotactic body radiation combined with immunotherapy found that the overall rate of severe treatment-related toxicity was roughly 12 to 15 percent whether the two were given concurrently or sequentially, with no consistent signal that adding radiation worsened the immunotherapy safety profile.²⁴

The Gut Microbiome Connection

The relationship between radiation and the immune system extends beyond the tumor itself. Growing evidence links the gut microbiome, the community of bacteria in the intestines, to both the effectiveness and the side effects of radiation therapy. The interaction runs in both directions: radiation disrupts the gut microbiome, particularly during abdominal or pelvic treatment, and changes in the microbiome can influence how well radiation and immunotherapy work. Gut bacteria may help determine whether a tumor’s microenvironment is “hot” (immune-active) or “cold” (immune-suppressed), which in turn affects whether radiation can generate a meaningful immune response.²⁵

On the damage side, radiation-induced shifts in gut bacteria contribute to radiation enteropathy, the nausea, diarrhea, and mucosal injury that many patients experience during treatment. These changes involve both the translocation of bacteria across a damaged gut lining and dysbiosis, a lasting imbalance in the microbial community. Research into whether certain bacterial species or their metabolites can protect the gut from radiation damage, or enhance the anti-tumor immune response, is active but still early.²⁶

How Age Alters the Equation

The immune effects of radiation are not the same in every patient, and age is one of the most important variables. The gradual decline in immune function that comes with aging, sometimes called immunosenescence, alters both the innate and adaptive arms of immunity. Older immune systems produce fewer naive T cells, have a higher proportion of exhausted or memory cells, and maintain a state of chronic low-grade inflammation. In this context, radiation may not generate the same quality of immunogenic signals that it does in younger patients. The balance can tilt toward prolonged inflammation and immune dysregulation rather than a productive anti-tumor response.²⁷

This has practical implications for treatment planning. A 40-year-old and a 75-year-old receiving the same radiation dose to the same tumor type may experience meaningfully different immune outcomes. The growing recognition that age shapes the radiation-immune interaction is one reason researchers are pushing for more personalized approaches, including biomarker-driven treatment selection. A gene expression assay tested in a prospective study of pelvic cancer patients, for instance, showed it could predict acute radiation toxicity from a pre-treatment blood sample with roughly 80 percent sensitivity and 90 percent specificity, hinting at a future where individual immune profiles guide decisions about dose, timing, and whether to add immunotherapy.²⁸

Bystander Signaling Between Cells

Not every immune-relevant effect of radiation requires the target cell to be hit directly. Irradiated cells communicate with their neighbors through gap junctions and secreted inflammatory molecules, a phenomenon called the bystander effect. These signals can cause DNA damage, stress responses, and altered gene expression in cells that were never touched by a photon or particle. In the context of tumors, bystander signaling may extend the immune-activating reach of radiation beyond the cells that were directly killed, amplifying the release of danger signals across a wider area of the tumor.²⁹ This adds yet another layer to the immune picture: the immune system responds not just to cells that were irradiated, but to their stressed and signaling neighbors as well.

Circadian Timing and Radiation Sensitivity

An underappreciated factor in radiation’s immune effects is the time of day treatment is delivered. Both healthy tissues and tumors show circadian rhythms in cell division, and the body’s immune cells follow their own daily cycles of activity. Animal studies have found clear circadian patterns in radiation sensitivity, with the highest toxicity occurring during the active phase of the day. Bone marrow and intestinal stem cells, both of which are critical for immune function and gut integrity, show time-dependent vulnerability to radiation damage.³⁰ The idea that scheduling radiation at certain times of day could improve the ratio of tumor killing to immune damage is appealing and has some experimental support, though it has yet to be widely adopted in clinical practice. For now, most treatment scheduling is driven by logistics rather than biology, but the concept of chronoradiotherapy sits at the intersection of radiation biology and immunology in a way that could matter more as treatment becomes more personalized.